THYSSENKRUPP NUCERA AG & CO (NCH2.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:NCH2 - DE000NCA0001 - Common Stock
7.75 EUR
-0.05 (-0.64%)
Overall NCH2 gets a fundamental rating of 4 out of 10. We evaluated NCH2 against 46 industry peers in the Construction & Engineering industry. While NCH2 seems to be doing ok healthwise, there are quite some concerns on its profitability. NCH2 is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
NCH2 had positive earnings in the past year.
NCH2 had a positive operating cash flow in the past year.
In the past 5 years NCH2 has always been profitable.
In multiple years NCH2 reported negative operating cash flow during the last 5 years.
1.2 Ratios
With a Return On Assets value of 1.09%, NCH2 is not doing good in the industry: 82.61% of the companies in the same industry are doing better.
The Return On Equity of NCH2 (1.80%) is worse than 82.61% of its industry peers.
Looking at the Return On Invested Capital, with a value of 0.08%, NCH2 is doing worse than 91.30% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.09% | ||
| ROE | 1.8% | ||
| ROIC | 0.08% |
ROA(3y)1.36%
ROA(5y)2.95%
ROE(3y)2.51%
ROE(5y)5.96%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NCH2's Profit Margin of 1.49% is on the low side compared to the rest of the industry. NCH2 is outperformed by 78.26% of its industry peers.
NCH2's Profit Margin has declined in the last couple of years.
NCH2's Operating Margin of 0.09% is on the low side compared to the rest of the industry. NCH2 is outperformed by 91.30% of its industry peers.
With a Gross Margin value of 11.22%, NCH2 is not doing good in the industry: 84.78% of the companies in the same industry are doing better.
NCH2's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 0.09% | ||
| PM (TTM) | 1.49% | ||
| GM | 11.22% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-42.36%
PM growth 5YN/A
GM growth 3Y-21.27%
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), NCH2 is destroying value.
Compared to 1 year ago, NCH2 has about the same amount of shares outstanding.
Compared to 1 year ago, NCH2 has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.71 indicates that NCH2 is not a great score, but indicates only limited risk for bankruptcy at the moment.
NCH2 has a better Altman-Z score (2.71) than 71.74% of its industry peers.
A Debt/Equity ratio of 0.03 indicates that NCH2 is not too dependend on debt financing.
NCH2 has a Debt to Equity ratio of 0.03. This is amongst the best in the industry. NCH2 outperforms 97.83% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.71 |
ROIC/WACC0.01
WACC7.24%
2.3 Liquidity
NCH2 has a Current Ratio of 2.48. This indicates that NCH2 is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 2.48, NCH2 belongs to the best of the industry, outperforming 97.83% of the companies in the same industry.
A Quick Ratio of 2.04 indicates that NCH2 has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 2.04, NCH2 belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.48 | ||
| Quick Ratio | 2.04 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 175.00% over the past year.
NCH2 shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -19.70% yearly.
Looking at the last year, NCH2 shows a decrease in Revenue. The Revenue has decreased by -4.88% in the last year.
Measured over the past years, NCH2 shows a very strong growth in Revenue. The Revenue has been growing by 39.21% on average per year.
EPS 1Y (TTM)175%
EPS 3Y-19.7%
EPS 5YN/A
EPS Q2Q%-120%
Revenue 1Y (TTM)-4.88%
Revenue growth 3Y39.21%
Revenue growth 5YN/A
Sales Q2Q%-21.93%
3.2 Future
Based on estimates for the next years, NCH2 will show a very strong growth in Earnings Per Share. The EPS will grow by 60.71% on average per year.
NCH2 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.19% yearly.
EPS Next Y-23.16%
EPS Next 2Y-12.15%
EPS Next 3Y31.99%
EPS Next 5Y60.71%
Revenue Next Year0.05%
Revenue Next 2Y-13.9%
Revenue Next 3Y-3.5%
Revenue Next 5Y12.19%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 70.45, the valuation of NCH2 can be described as expensive.
Based on the Price/Earnings ratio, NCH2 is valued a bit more expensive than 76.09% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.54, NCH2 is valued quite expensively.
A Price/Forward Earnings ratio of 111.57 indicates a quite expensive valuation of NCH2.
NCH2's Price/Forward Earnings ratio is rather expensive when compared to the industry. NCH2 is more expensive than 80.43% of the companies in the same industry.
NCH2 is valuated expensively when we compare the Price/Forward Earnings ratio to 23.78, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 70.45 | ||
| Fwd PE | 111.57 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of NCH2 indicates a slightly more expensive valuation: NCH2 is more expensive than 76.09% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 29.46 |
4.3 Compensation for Growth
NCH2's earnings are expected to grow with 31.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-12.15%
EPS Next 3Y31.99%
5. Dividend
5.1 Amount
NCH2 does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:NCH2 (12/12/2025, 5:29:09 PM)
7.75
-0.05 (-0.64%)
Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryConstruction & Engineering
Earnings (Last)
Earnings (Next)
Inst Owners15.82%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap978.90M
Revenue(TTM)912.00M
Net Income(TTM)13.60M
Analysts74.74
Price Target11.17 (44.13%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-9.09%
Min Revenue beat(2)-12.43%
Max Revenue beat(2)-5.74%
Revenue beat(4)1
Avg Revenue beat(4)-2.5%
Min Revenue beat(4)-12.43%
Max Revenue beat(4)10.74%
Revenue beat(8)1
Avg Revenue beat(8)-6.07%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-8.43%
PT rev (3m)-8.37%
EPS NQ rev (1m)25%
EPS NQ rev (3m)25%
EPS NY rev (1m)3.04%
EPS NY rev (3m)-15.06%
Revenue NQ rev (1m)-8.64%
Revenue NQ rev (3m)-12.37%
Revenue NY rev (1m)-2.65%
Revenue NY rev (3m)-3.21%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 70.45 | ||
| Fwd PE | 111.57 | ||
| P/S | 1.07 | ||
| P/FCF | N/A | ||
| P/OCF | 50.98 | ||
| P/B | 1.3 | ||
| P/tB | 1.43 | ||
| EV/EBITDA | 29.46 |
EPS(TTM)0.11
EY1.42%
EPS(NY)0.07
Fwd EY0.9%
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)0.15
OCFY1.96%
SpS7.22
BVpS5.97
TBVpS5.42
PEG (NY)N/A
PEG (5Y)N/A
Graham Number3.84
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.09% | ||
| ROE | 1.8% | ||
| ROCE | 0.1% | ||
| ROIC | 0.08% | ||
| ROICexc | 0.58% | ||
| ROICexgc | 1.54% | ||
| OM | 0.09% | ||
| PM (TTM) | 1.49% | ||
| GM | 11.22% | ||
| FCFM | N/A |
ROA(3y)1.36%
ROA(5y)2.95%
ROE(3y)2.51%
ROE(5y)5.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-42.36%
PM growth 5YN/A
GM growth 3Y-21.27%
GM growth 5YN/A
F-Score4
Asset Turnover0.73
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 2.31 | ||
| Cap/Depr | 261% | ||
| Cap/Sales | 2.86% | ||
| Interest Coverage | 1 | ||
| Cash Conversion | 177.78% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.48 | ||
| Quick Ratio | 2.04 | ||
| Altman-Z | 2.71 |
F-Score4
WACC7.24%
ROIC/WACC0.01
Cap/Depr(3y)106.05%
Cap/Depr(5y)76.37%
Cap/Sales(3y)0.81%
Cap/Sales(5y)0.64%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)175%
EPS 3Y-19.7%
EPS 5YN/A
EPS Q2Q%-120%
EPS Next Y-23.16%
EPS Next 2Y-12.15%
EPS Next 3Y31.99%
EPS Next 5Y60.71%
Revenue 1Y (TTM)-4.88%
Revenue growth 3Y39.21%
Revenue growth 5YN/A
Sales Q2Q%-21.93%
Revenue Next Year0.05%
Revenue Next 2Y-13.9%
Revenue Next 3Y-3.5%
Revenue Next 5Y12.19%
EBIT growth 1Y126.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year136.01%
EBIT Next 3Y44.53%
EBIT Next 5Y41.71%
FCF growth 1Y-341.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-376.92%
OCF growth 3YN/A
OCF growth 5YN/A
THYSSENKRUPP NUCERA AG & CO / NCH2.DE FAQ
What is the fundamental rating for NCH2 stock?
ChartMill assigns a fundamental rating of 4 / 10 to NCH2.DE.
What is the valuation status of THYSSENKRUPP NUCERA AG & CO (NCH2.DE) stock?
ChartMill assigns a valuation rating of 1 / 10 to THYSSENKRUPP NUCERA AG & CO (NCH2.DE). This can be considered as Overvalued.
How profitable is THYSSENKRUPP NUCERA AG & CO (NCH2.DE) stock?
THYSSENKRUPP NUCERA AG & CO (NCH2.DE) has a profitability rating of 2 / 10.
What is the valuation of THYSSENKRUPP NUCERA AG & CO based on its PE and PB ratios?
The Price/Earnings (PE) ratio for THYSSENKRUPP NUCERA AG & CO (NCH2.DE) is 70.45 and the Price/Book (PB) ratio is 1.3.
What is the financial health of THYSSENKRUPP NUCERA AG & CO (NCH2.DE) stock?
The financial health rating of THYSSENKRUPP NUCERA AG & CO (NCH2.DE) is 6 / 10.